Impact of Proviral-DNA M184V/I on 96-Week Outcomes of DTG/3TC Maintenance Therapy: Results From the VOLVER Clinical Trial

20260 citationsJournal Article

Authors

María De Lagarde · Universidad Complutense de Madrid

Rosa de Miguel · Hospital Universitario La Paz

Mayra A Sigcha · Research Institute Hospital 12 de Octubre

José Luis Blanco · Universidad Complutense de Madrid

Adriana Pinto-Martinez · Research Institute Hospital 12 de Octubre

Rocío Montejano · Hospital Universitario La Paz

Angela Gutiérrez Liarte ·

Abstract

Proviral-DNA M184V/I detection was not associated with virological outcomes in participants receiving DTG/3TC supporting its limited clinical value in this specific setting.

Topics & Keywords

HIV/AIDS drug development and treatment Hepatitis B Virus Studies Hepatitis C virus research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Infectious Diseases

DOI: 10.1093/cid/ciag060

Field-Weighted Citation Impact: 0.00